930 related articles for article (PubMed ID: 25907999)
1. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
2. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Ocular Pulse Amplitude-Lowering Effects of Tafluprost and Latanoprost by Dynamic Contour Tonometry.
Park SH; Yoo SH; Ha SJ
J Ocul Pharmacol Ther; 2015 Dec; 31(10):617-22. PubMed ID: 26348718
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.
Suzuki K; Otsuka N; Hizaki H; Hashimoto M; Kuwayama Y;
Adv Ther; 2018 Jun; 35(6):796-808. PubMed ID: 29873009
[TBL] [Abstract][Full Text] [Related]
6. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
Wong TT; Aung T; Ho CL
Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
[TBL] [Abstract][Full Text] [Related]
7. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
[TBL] [Abstract][Full Text] [Related]
8. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
[TBL] [Abstract][Full Text] [Related]
9. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
Gandolfi SA; Cimino L
Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension.
Digiuni M; Manni G; Vetrugno M; Uva M; Milano G; Orzalesi N; Fogagnolo P; Centofanti M; Campos E; Rossetti L
J Glaucoma; 2013 Dec; 22(9):707-12. PubMed ID: 22595934
[TBL] [Abstract][Full Text] [Related]
12. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
Traverso CE; Ropo A; Papadia M; Uusitalo H
J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
[TBL] [Abstract][Full Text] [Related]
13. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension.
Narayanaswamy A; Neog A; Baskaran M; George R; Lingam V; Desai C; Rajadhyaksha V
Indian J Ophthalmol; 2007; 55(2):127-31. PubMed ID: 17322603
[TBL] [Abstract][Full Text] [Related]
14. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
15. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.
Eveleth D; Starita C; Tressler C
BMC Ophthalmol; 2012 May; 12():9. PubMed ID: 22607109
[TBL] [Abstract][Full Text] [Related]
16. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
17. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
Kuwayama Y; Nomura A
Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.
DuBiner H; Cooke D; Dirks M; Stewart WC; VanDenburgh AM; Felix C
Surv Ophthalmol; 2001 May; 45 Suppl 4():S353-60. PubMed ID: 11434938
[TBL] [Abstract][Full Text] [Related]
19. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]